Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 36

Similar articles for PubMed (Select 21376587)

1.

Hybrid compounds as new Bcr/Abl inhibitors.

Wang D, Zhang Z, Lu X, Feng Y, Luo K, Gan J, Yingxue L, Wan J, Li X, Zhang F, Tu Z, Cai Q, Ren X, Ding K.

Bioorg Med Chem Lett. 2011 Apr 1;21(7):1965-8. doi: 10.1016/j.bmcl.2011.02.029. Epub 2011 Feb 13.

PMID:
21376587
2.

Establishment of a new Philadelphia chromosome-positive acute lymphoblastic leukemia cell line (SK-9) with T315I mutation.

Okabe S, Tauchi T, Ohyashiki K.

Exp Hematol. 2010 Sep;38(9):765-72. doi: 10.1016/j.exphem.2010.04.017. Epub 2010 May 13.

PMID:
20471447
3.

Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors.

Asaki T, Sugiyama Y, Hamamoto T, Higashioka M, Umehara M, Naito H, Niwa T.

Bioorg Med Chem Lett. 2006 Mar 1;16(5):1421-5. Epub 2005 Dec 5.

PMID:
16332440
4.

Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.

Nguyen TK, Rahmani M, Gao N, Kramer L, Corbin AS, Druker BJ, Dent P, Grant S.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2239-47.

5.

Design, synthesis and evaluation of (E)-alpha-benzylthio chalcones as novel inhibitors of BCR-ABL kinase.

Reddy MV, Pallela VR, Cosenza SC, Mallireddigari MR, Patti R, Bonagura M, Truongcao M, Akula B, Jatiani SS, Reddy EP.

Bioorg Med Chem. 2010 Mar 15;18(6):2317-26. doi: 10.1016/j.bmc.2010.01.051. Epub 2010 Jan 25.

PMID:
20188579
6.

Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.

Mahboobi S, Dove S, Sellmer A, Winkler M, Eichhorn E, Pongratz H, Ciossek T, Baer T, Maier T, Beckers T.

J Med Chem. 2009 Apr 23;52(8):2265-79. doi: 10.1021/jm800988r.

PMID:
19301902
7.

Characterization of compound 584, an Abl kinase inhibitor with lasting effects.

Puttini M, Redaelli S, Moretti L, Brussolo S, Gunby RH, Mologni L, Marchesi E, Cleris L, Donella-Deana A, Drueckes P, Sala E, Lucchini V, Kubbutat M, Formelli F, Zambon A, Scapozza L, Gambacorti-Passerini C.

Haematologica. 2008 May;93(5):653-61. doi: 10.3324/haematol.12212. Epub 2008 Mar 26.

8.

New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.

O'Hare T, Eide CA, Deininger MW.

Expert Opin Investig Drugs. 2008 Jun;17(6):865-78. doi: 10.1517/13543784.17.6.865 . Review.

PMID:
18491988
9.

Design, synthesis and biological evaluation of novel acrylamide analogues as inhibitors of BCR-ABL kinase.

Li S, Yao Z, Zhao Y, Chen W, Wang H, Kuang X, Zhan W, Yao S, Yu S, Hu W.

Bioorg Med Chem Lett. 2012 Aug 15;22(16):5279-82. doi: 10.1016/j.bmcl.2012.06.044. Epub 2012 Jun 21.

PMID:
22789429
10.

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.

O'Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA 3rd, Bohacek RS, Wang Y, Sundaramoorthi R, Shakespeare WC, Dalgarno D, Clackson T, Sawyer TK, Deininger MW, Druker BJ.

Blood. 2004 Oct 15;104(8):2532-9. Epub 2004 Jul 15.

11.

Design, synthesis and biological activities of Nilotinib derivates as antitumor agents.

Pan X, Wang F, Zhang Y, Gao H, Hu Z, Wang S, Zhang J.

Bioorg Med Chem. 2013 May 1;21(9):2527-34. doi: 10.1016/j.bmc.2013.02.036. Epub 2013 Mar 5.

PMID:
23538233
12.

Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells.

Bartholomeusz GA, Talpaz M, Kapuria V, Kong LY, Wang S, Estrov Z, Priebe W, Wu J, Donato NJ.

Blood. 2007 Apr 15;109(8):3470-8. Epub 2007 Jan 3.

13.

Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases.

Wisniewski D, Lambek CL, Liu C, Strife A, Veach DR, Nagar B, Young MA, Schindler T, Bornmann WG, Bertino JR, Kuriyan J, Clarkson B.

Cancer Res. 2002 Aug 1;62(15):4244-55.

14.

Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107).

von Bubnoff N, Manley PW, Mestan J, Sanger J, Peschel C, Duyster J.

Blood. 2006 Aug 15;108(4):1328-33. Epub 2006 Apr 13.

15.

Identification of novel inhibitors of BCR-ABL tyrosine kinase via virtual screening.

Peng H, Huang N, Qi J, Xie P, Xu C, Wang J, Yang C.

Bioorg Med Chem Lett. 2003 Nov 3;13(21):3693-9.

PMID:
14552760
16.

Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib.

Dillmann F, Veldwijk MR, Laufs S, Sperandio M, Calandra G, Wenz F, Zeller J, Fruehauf S.

Leuk Lymphoma. 2009 Oct;50(10):1676-86. doi: 10.1080/10428190903150847.

PMID:
19657955
17.

New thiazole carboxamides as potent inhibitors of Akt kinases.

Chang S, Zhang Z, Zhuang X, Luo J, Cao X, Li H, Tu Z, Lu X, Ren X, Ding K.

Bioorg Med Chem Lett. 2012 Jan 15;22(2):1208-12. doi: 10.1016/j.bmcl.2011.11.080. Epub 2011 Nov 30.

PMID:
22172705
18.

[Establishment of an imatinib resistant cell line K562/G01 and its characterization].

Qi J, Peng H, Gu ZL, Liang ZQ, Yang CZ.

Zhonghua Xue Ye Xue Za Zhi. 2004 Jun;25(6):337-41. Chinese.

PMID:
15308010
19.

Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.

Deremer DL, Ustun C, Natarajan K.

Clin Ther. 2008 Nov;30(11):1956-75. doi: 10.1016/j.clinthera.2008.11.014. Review.

PMID:
19108785
20.

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia.

Golemovic M, Verstovsek S, Giles F, Cortes J, Manshouri T, Manley PW, Mestan J, Dugan M, Alland L, Griffin JD, Arlinghaus RB, Sun T, Kantarjian H, Beran M.

Clin Cancer Res. 2005 Jul 1;11(13):4941-7.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk